Spots Global Cancer Trial Database for Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant

Official Title: Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant for Multiple Myeloma

Study ID: NCT00839956

Conditions

DS Stage I Plasma Cell Myeloma

DS Stage II Plasma Cell Myeloma

DS Stage III Plasma Cell Myeloma

Interventions

Bortezomib

Vorinostat

Study Description

Brief Summary: This phase II trial studies the side effects of giving bortezomib together with vorinostat and to see how well it works in treating patients with multiple myeloma who have undergone autologous stem cell transplant. Bortezomib and vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with vorinostat after an autologous stem cell transplant may stop the growth of any cancer cells that remain after transplant.

Detailed Description: PRIMARY OBJECTIVES: I. Evaluate the toxicity of the use of vorinostat and bortezomib as maintenance therapy after autologous transplant. SECONDARY OBJECTIVES: I. Evaluate the median time to disease progression. II. Evaluate survival. OUTLINE: Patients receive bortezomib intravenously (IV) on days 2 and 5 and vorinostat orally (PO) once daily (QD) on days 1-14. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically.